Calypso Medical Technologies, Inc.

Calypso Medical Technologies, Inc. focuses on developing advanced localization and tracking solutions for cancer treatment, enhancing the precision of radiotherapy and ensuring optimal patient outcomes. Calypso Medical Technologies was founded in 1999 in Seattle, US, and specializes in providing innovative solutions for cancer treatment. The company was acquired by Varian Medical Systems, Inc.

in September 2011 for USD 10 million, which included milestone payments. The acquisition aligns with Varian's strategic focus on advancing cancer care technologies. Varian has a history of integrating innovative companies to expand its portfolio and capabilities within the oncology sector. Calypso Medical Technologies offers advanced localization and tracking technologies for cancer treatment, specifically designed to enhance the precision of radiation therapy.

The company’s core products are utilized in oncology centers around the globe, addressing critical needs in tumor tracking and treatment planning to improve patient safety and outcomes. Calypso's solutions cater to various healthcare institutions, ranging from large hospitals to specialized cancer clinics, ensuring effective treatment delivery. Calypso Medical Technologies generates revenue primarily through the sale of its cancer treatment localization systems, which are sold directly to hospitals and oncology centers. Additional revenue comes from service contracts and ongoing support agreements that maintain operational efficiency.

The pricing reflects the advanced nature of its products and their critical role in ensuring effective cancer therapy. Following its acquisition by Varian Medical Systems, Calypso Medical Technologies is poised for growth through the integration of new technologies and expansion into emerging markets. The recent acquisition deal, completed in September 2011, is expected to enhance the availability of its tracking solutions, supporting Varian's strategic initiatives to introduce new products into the oncology space. The company plans to focus on expanding its presence in Europe and Asia-Pacific by 2023 as part of its growth strategy.